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ORIGINAL ARTICLE
Background/Aims: The risk of venous thromboembolism (VTE), which encompasses deep vein thrombosis and
pulmonary embolism (PE), increases in patients with cancer. Anticancer treatment is also associated with an
increased risk for VTE. We conducted this study to investigate the clinical characteristics of patients with cancer
and PE related to anticancer treatment in a tertiary care hospital in Korea.
Methods: We retrospectively reviewed the clinical data of patients with an underlying malignancy who were
diagnosed with PE by chest computed tomography (CT) with or without lower extremity CT angiography between
January 2006 and December 2007 at Seoul National University Hospital. 
Results: Overall, 95 patients with malignancies among 168 with PE were analyzed. The median age was 64
years. The median time interval from the malignancy diagnosis to the PE diagnosis was 5.5 months. Lung cancer
was the most common malignancy (23.0%), followed by pancreatobiliary cancer, stomach cancer, gynecological
cancer, breast cancer, and hepatocellular carcinoma. Platinum-containing and pyrimidine analog-containing
chemotherapeutic regimens were common. 
Conclusions: PE was diagnosed within 1 year after the cancer diagnosis in almost 70% of patients. Lung cancer
was the most common underlying malignancy. (Korean J Intern Med 2010;25:66-70)
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INTRODUCTION
The risk of venous thromboembolism (VTE) now well
recognized to increase in patients with cancer. Silverstein
et al. [1] reported that the annual incidence of a first
episode of deep vein thrombosis (DVT) or pulmonary
embolism (PE) in the general population is 117 in 100,000.
Cancer alone was associated with a 4.1-fold risk for
thrombosis. More recently, Blom et al. [2] reported that
the overall risk for venous thrombosis increases 7-fold in
patients with a malignancy.  
The relationship between VTE and anticancer treatment
has been investigated. In a retrospective study in patients
who underwent chemotherapy, the annual rate of throm-
boembolic complications arising within the first 3 months
was 11% [3]. In a prospective observational study among
3,003 patients treated with at least one cycle of chemother-
apy, VTE occurred in 58 (1.93%) over a median follow-up
of 2.4 months [4]. 
Although DVT and PE encompass one disease entity,
important differences exist. The major adverse outcome of
DVT alone is the development of postphlebitic syndrome.
However, PE can be fatal or cause chronic thromboembolic
pulmonary hypertension. 
We conducted this study in a single tertiary referral
hospital in Korea to investigate the clinical characteristicsLee JE, et al. Pulmonary embolism with underlying malignancy    67
of cancer patients with PE.  
METHODS
Study population
We screened 168 patients who were diagnosed with PE
by chest computed tomography (CT) with or without
lower extremity CT angiography at Seoul National
University Hospital between January 2006 and December
2007. The malignant diseases were diagnosed according
to current standards using histological and/or cytological
reports. This study was approved by the institutional
review board of Seoul National University Hospital, which
waived the informed consent requirement for individual
patients due to the retrospective nature of the study. 
Data collection 
Other than patient age and gender, Eastern Cooperative
Oncology Group (ECOG) performance scores and
comorbidities such as diabetes mellitus, hypertension,
congestive heart failure, coronary artery disease, cere-
brovascular disease, and chronic renal disease were
reviewed. The kind of malignant disease and the various
chemotherapeutic agents administered to each patient
were recorded. We reviewed the exact dates that chemother-
apy was started and stopped. The exact dates the
radiotherapy was started and stopped were also recorded
for patients given radiotherapy. The exact date of any kind
of surgery was also recorded. 
We considered that PE diagnosed during the treatment
or within 13 weeks after the last treatment was related to
treatment, analogous to postsurgical patients [3].
RESULTS
Of the 168 patients who were diagnosed with PE, 99
had an underlying malignancy. Of the 99 patients, four
were excluded because no evidence of disease was observed
over the 5 years after anticancer treatments had been
finished. 
Patient characteristics
The clinical characteristics of the 95 patients are shown
in Table 1. The median age was 64 years. More than half of
the patients were in ECOG performance status 0-1, and
only 8 patients (8.5%) were in a poor performance status
[3,4]. More than 25% of the patients had hypertension
and 63 (66.3%) had symptoms associated with PE or
DVT. Dyspnea was the most frequent symptom. Eighty-
four patients (88.4%) had distant cancer metastasis at the
Table 1. Study population characteristics
Characteristics Number of patients
(n = 95)
Age, yr 64 (31 - 91)
Gender
Male 52 (54.7)
Female 43 (45.3)
Body mass Index, kg/m
2 22.90 ± 3.48
Performance status (ECOG)
0 4 (4.2)
1 54 (56.8)
2 29 (30.5)
3 1 (1.1)
4 7 (7.4)
Comorbidities
Diabetes mellitus 16 (16.8)
Hypertension 24 (25.3)
Congestive heart failure 2 (2.1)
Coronary artery disease 2 (2.1)
Cerebrovascular disease 2 (2.1)
Renal disease 3 (3.2)
Type of VTE
Chest CT with L/E CT angiography 73 (76.8)
PE without DVT 18 (18.9)
PE with DVT 55 (57.9)
Chest CT only 22 (23.2)
Symptom
Present 63 (66.3)
Dyspnea    44 (46.3)
Deep vein thrombosis symptom 14 (14.7)
Chest pain 4 (4.2)
Others 1 (1.1)
Absent 32 (33.7)
Distant metastasis
Present 84 (88.4)
Absent 11 (11.6)
Surgery 34 (35.8)
Recent (within 13 wk) 12 (12.6)
Chemotherapy 67 (70.5)
Radiotherapy 24 (25.3)
Values are presented as median (range) or number (%) unless
otherwise indicated.
ECOG, Eastern Cooperative Oncology Group; VTE, venous
thromboembolism; CT, computed tomography; L/E, lower
extremity; PE, pulmonary embolism; DVT, deep vein thrombosis.68 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010
time of PE diagnosis. 
Eleven patients (11.6%) were diagnosed with malignancy
after the PE diagnosis. The median time interval from
malignancy diagnosis to PE diagnosis was 5.5 months,
and PE was diagnosed within 1 year after the malignancy
diagnosis in almost 70% of the patients (Fig. 1). 
Lung cancer was the most common malignancy (23.0%),
followed by pancreatobiliary cancer, stomach cancer,
gynecological cancer, breast cancer, and hepatocellular
carcinoma (Fig. 2). 
Chemotherapy / Radiotherapy
Sixty-seven (70.5%) patients were treated with
chemotherapy. Of these, PE was diagnosed during the
treatment or within 13 weeks after chemotherapy in 52.
The median duration for chemotherapeutic treatment was
12.1 weeks (interquartile range [IQR], 6.0 to 27.2). A
platinum-containing regimen (55.8%) was the most
common, followed by a pyrimidine analog-containing
regimen and a taxane-containing regimen (Table 2). 
Twenty-five patients were treated with radiotherapy. Of
the 25, PE was diagnosed either during the treatment or
within 13 weeks after radiotherapy (10 patients). The
median radiotherapy duration was 14.3 days (IQR, 13.2 to
22.0; Table 2).
DISCUSSION
The risk for VTE increases in patients with cancer. In
the current study, the median time interval from cancer
diagnosis to PE diagnosis was 5.5 months, and 70% of
the patients were diagnosed with PE within 1 year after
the cancer diagnosis. Almost 90% of the patients had
metastatic disease. In a previous cohort study including
235,149 patients with cancer [5], the incidence of a
thromboembolic event among patients with either
metastatic- or regional-stage disease was highest in the
first few months after diagnosis, and the incidence
decreased over time for most cancers. In a case-control
study of patients with acute VTE [2], the incidence of VTE
was highest in the first 6 months after the cancer diagnosis.
In another lung cancer cohort study [6], the VTE incidence
Table 2. Details of chemotherapy/radiotherapy related
to pulmonary embolism
Chemotherapy / Radiotherapy Number of patients
(n = 62)
Chemotherapy
All patients  52 (77.6% of 67 patients)
Duration of chemotherapy, wk   12.1 (6.0 - 27.2)
Time after the start of chemotherapy, wk 16.6 (8.4 - 31.6)
Type of chemotherapeutic agent
Platinum-containing 32 (61.5)
Pyrimidine analogue-containing 29 (55.8)
Taxane-containing 8 (15.4)
Anthracycline-containing 5 (9.6)
Radiotherapy
All patients  10 (41.7% of 24 patients)
Duration of radiotherapy, day   14.25 (13.2 - 22.0)
Time after the start of radiotherapy, day 62.5 (24.0 - 90.7)
Values are presented number (%) or median (IQR) unless
otherwise indicated.
IQR, interquartile range.
Figure 1. Interval between cancer and pulmonary embolism
diagnoses. A venous thromboembolism was diagnosed within 1
yr after detecting a malignancy in almost 70% of the patients.
Figure 2. Types of malignancy. Lung cancer was the most
common malignancy, followed by pancreatobiliary cancer and
stomach cancer.Lee JE, et al. Pulmonary embolism with underlying malignancy    69
rate was highest in the first 6 months after the cancer
diagnosis, averaging 7.2 VTE events/100 patient-years.
Patients with distant metastasis are at an increased risk
for VTE [2,5-9], and the current study findings are
consistent with these previous studies. As noted previously
[5], the biological aggressiveness of cancer may be the
principal risk factor associated with the development of
thromboembolism. However, considering that 52 among
95 patients were diagnosed with PE during or within
13 weeks after chemotherapy in the current study, the
possibility also exists that anticancer treatment in the
months immediately following the cancer diagnosis may
have contributed to the high incidence of thromboembolism.
Among autopsy-proven patients with PE, 83% had DVT
in the legs [10]. That is, only 17% of the patients had PE
without DVT. In this study, among the 73 patients who
were evaluated with both chest CT and lower extremity CT
angiography, 18 (24.7%) had no evidence of DVT;
however, a direct comparison with previous autopsy data
is irrelevant. In a recent Japanese prospective study,
patients with PE alone represented 40% of all patients
with PE [11]. Due to the retrospective nature of the present
study, lower-extremity CT may have been performed on
patients who were more likely to have DVT. 
In the present study, 11 patients (11.6%) were diagnosed
with malignancy after the PE diagnosis. On the basis of
results from cohort studies and clinical trials, up to 10% of
patients presenting with idiopathic VTE are subsequently
diagnosed with an underlying and previously undiagnosed
malignancy [12-16]. Although extensive screening of
patients with VTE may result in the early identification of
hidden cancer, whether the prognosis of the malignancy
can be favorably influenced is unknown [17,18]. 
Gastrointestinal cancer, lung cancer, and hematological
cancer are associated with a very high risk for venous
thrombosis [2]. In another prospective observational
study [4], the highest rates of VTE occurred in patients
with upper gastrointestinal cancers (including gastric,
pancreatic, and hepatobiliary) and lung cancer. Similarly,
lung cancer (23.0%) and upper gastrointestinal cancer
(28.0%) were common in the present study. However, this
finding may have resulted from the high prevalence of
these kinds of cancers, as stomach, lung, colon, liver, and
the pancreatobiliary system are the most common sites of
malignancy in Korea [19]. As described in Table 2,
pancreatobiliary cancers were the second most common
underlying malignancy, although pancreatobiliary cancers
account for only 5.5% of cancers in Korea [19]. Frequent
use of pyrimidine analogs (especially gemcitabine) in
these cancers might be one of the possible explanations.
In this study, 10 of the 15 patients with pancreatobiliary
cancer were treated with a chemotherapeutic regimen
containing pyrimidine analogs. The advanced stage of
pancreatobiliary cancer diagnosis in most of the patients
may be another cause for the relatively high PE incidence.  
Chemotherapeutic agents associated with a high risk for
VTE are not well known. In a previous prospective study
[4], the particular type of chemotherapy regimen was not
significantly associated with VTE. Pyrimidine analog-
containing and platinum-containing regimens were
common in this study (55.8%); however, these agents are
widely used as first-line chemotherapy in lung and
gastrointestinal cancer, which are the most common
cancers in Korea. These kinds of chemotherapeutic agents
cannot be concluded to be associated with an increased
risk for VTE. 
However, in an experimental model, the endothelium of
fluorouracil-treated rabbits was badly damaged, leading
to intima disruption and denudation of underlying
structures with accompanying platelet accumulation
and fibrin deposition [20]. A significant increase in
fibrinopeptide A levels in patients treated with fluorouracil
has been reported [21,22]. Furthermore, VTE was most
frequent in patients treated with five daily bolus injections
of fluorouracil-leucovorin every months (6 [15%] of these
41 patients had VTE; 95% confidence interval, 6 to 29) [3].
Pyrimidine analogs may be more associated with an
increased risk for VTE than other kinds of chemother-
apeutic drugs. Further investigation is needed. 
Data about the relationship between VTE and radiotherapy
are lacking. In a record linkage study, the risk of VTE did
not increase for patients who underwent radiotherapy
[23]. Further study is needed to investigate the role of
radiotherapy in the development of VTE. 
This study has several limitations. Because of its
retrospective nature, probable or possible patients with PE
who did not have chest CT were not been included, and
cases of PE diagnosed by lung perfusion/ventilation or
pulmonary angiogram were also not included. 
In summary, the median time interval from cancer to
PE diagnosis was 5.5 months, and almost 90% of the
patients had metastatic disease. Lung cancer was the most
common underlying malignancy.70 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010
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